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Tissue transglutaminase in astrocytes is
enhanced by inflammatory mediators and
is involved in the formation of fibronectin
fibril-like structures
Nathaly Espitia Pinzón1, John J. P. Brevé1, John G. J. M. Bol1, Benjamin Drukarch1, Wia Baron2†
and Anne-Marie van Dam1*†
Abstract
Background: During multiple sclerosis (MS) lesion formation, inflammatory mediators are produced by microglial
cells and invading leukocytes. Subsequently, hypertrophic astrocytes fill the lesion and produce extracellular matrix
(ECM) proteins that together form the astroglial scar. This is beneficial because it seals off the site of central nervous
system (CNS) damage. However, astroglial scarring also forms an obstacle that inhibits remyelination of brain
lesions. This is possibly an important cause for incomplete remyelination of the CNS in early stage MS patients and
for failure of remyelination when the disease progresses. Tissue transglutaminase (TG2), a Ca2+-dependent enzyme
that can cross-link proteins, appears in astrocytes in inflammatory MS lesions and may contribute to the
rearrangement of ECM protein deposition and aggregation.
Methods: The effect of different inflammatory mediators on TG2 and fibronectin, an ECM protein, protein levels
was examined in primary rat microglia and astrocytes by western blotting. Also, TG2 activity was analyzed in
primary rat astrocytes by a TG activity assay. To determine the role of TG2 in the deposition and cross-linking of
fibronectin, a TG2 inhibitor and TG2 knockdown astrocytes were used.
Results: Our data show that under inflammatory conditions in vitro, TG2 production is enhanced in astrocytes and
microglia. We observed that in particular, astrocytes produce fibronectin that can be cross-linked and aggregated by
exogenous TG2. Moreover, inflammatory stimulus-induced endogenously produced TG2 is involved in the appearance
of morphological fibril-like fibronectin deposits but does not lead to cross-linked fibronectin aggregates.
Conclusions: Our in vitro observations suggest that during MS lesion formation, when inflammatory mediators are
produced, astrocyte-derived TG2 may contribute to ECM rearrangement, and subsequent astroglial scarring.
Keywords: Tissue transglutaminase, Neuroinflammation, Astrocytes, Astroglial scarring, Extracellular matrix, Fibronectin
Background
In multiple sclerosis (MS), a chronic inflammatory, demye-
linating disease of the central nervous system (CNS),
various classes of inflammatory white matter lesions can be
identified [1, 2]. Active white matter lesions appear with a
massive influx of leukocytes and ongoing demyelination. In
these lesions, e.g., inflammatory cytokines and chemokines
are produced by activated microglial cells and invading
leukocytes [1, 3–6]. In chronic MS lesions, infiltrating cells,
particularly macrophages, remain present at the rim of the
lesion where demyelination is still ongoing [7]. Simultan-
eously, astrogliosis appears in the lesion which mainly con-
sists of astrocytes with a hypertrophic phenotype [8–11].
The formed astroglial scar is beneficial because it
seals of inflammation in the CNS into focal areas
[12]. However, the scar also impedes remyelination by
inhibiting the migration and differentiation of
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oligodendrocyte precursor cells [13]. Remyelination in
MS lesions is therefore not very effective [14–16],
which might contribute to the chronic neurodegener-
ative character of this disease with progressive loss of
motor, sensory, and cognitive functions [17].
During astrogliosis, the extracellular matrix (ECM) is
largely modified, which is reflected by an enhanced pro-
duction of ECM proteins by astrocytes [18–22]. Previ-
ous studies, under in vitro conditions, in MS animal
models and in brain material from patients already
showed changes in the production and deposition of
chondroitin sulfate proteoglycans, a family of ECM pro-
teoglycans [23, 24]. Furthermore, the ECM proteins
fibronectin and laminin have been shown to be more
expressed by astrocytes [25–28] and aggregated in chron-
ically demyelinated multiple sclerosis lesions [29], possibly
contributing to the non-regenerative nature of these
lesions [30, 31].
Tissue transglutaminase (TG2) is a Ca2+-dependent
enzyme with various catalytic functions, including
protein deamidation, transamidation, and cross-linking
[32–38]. TG2 is localized intracellularly [39], on the
cell surface and in the ECM [40, 41]. In the ECM,
TG2 is capable of cross-linking a wide range of pro-
teins, which are important in ECM deposition and
stabilization [42, 43]. TG2 can also directly, i.e., non-
enzymatically, interact with fibronectin, an important
ECM protein in tissue repair processes, and various
beta-integrins, thereby mediating cell-ECM interac-
tions [44–46]. TG2 is therefore thought to play an
important role in various physiological and patho-
logical situations including inflammation and fibrosis
[36, 47] and can possibly contribute to the process of
astroglial scarring in the CNS of MS patients and
other brain injuries.
We have previously shown the appearance of TG2
immunoreactivity in astrocytes in active and chronic
active MS lesions [48] and in demyelinating areas in the
mouse brain after cuprizone treatment [49]. Moreover,
TG2 expression in astrocytes is regulated by some
inflammatory mediators as are present in MS lesions
[50]. In the present study, we questioned whether a wide
array of inflammatory mediators can affect TG2 produc-
tion in astrocytes and possibly also in microglia which
can be a source of ECM proteins during the formation
of the astroglial scar [51–56]. We also questioned
whether TG2 contributes to the production, deposition,
and cross-linking of the ECM protein fibronectin under
inflammatory conditions. A better understanding of the
inflammatory regulation of TG2 and its role in the pro-
duction, deposition, and cross-linking of ECM proteins
by astrocytes and possibly microglia could be of thera-
peutic interest to overcome astroglial scarring and pro-
mote a remyelinating milieu.
Methods
Primary astrocytes and microglia
Primary rat glial cells were isolated from cerebral cortices of
2-day-old Wistar rats (Harlan CPB, Zeist, The Netherlands),
as described previously [57], and approved by the Animal
Experiment Committee of the VU University Medical
Center (ID FGA 11-03). The meninges and blood vessels
were removed from the cortices. Cortices were mechanically
homogenized in Dulbecco’s Modified Eagle’s Medium-F10
(Gibco, Life Technologies, Breda, The Netherlands), supple-
mented with 10% v/v heat-inactivated fetal calf serum
(Gibco), 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO,
USA), 50 U/ml penicillin (Sigma-Aldrich), and 50 μg/ml
streptomycin (Gibco) to make a cell suspension. Dissociated
cells from 2 to 3 pups were plated in poly-L-lysine (PLL,
15 μg/ml (2 μg/cm2); Sigma-Aldrich) coated T75 culture
flasks (Nunc, Hamstrop, Denmark) and incubated at 37 °C
in humidified air containing 5% CO2. The medium was
changed at days 1, 6, and 8 after seeding. After 10 days in
culture, microglia and astrocytes were separated by shaking
the flasks on a rotary platform (Heidolph Unimax 2010) at
230 rpm for 16 h. Astrocytes were further purified by treat-
ment with 5 mM leucine methyl ester (Sigma-Aldrich) in
serum-free medium, for 24 h at 37 °C. Microglia were
cultured in fresh medium mixed with conditioned medium
(1:1 ratio) collected from the mixed cell culture before
separation. The purity of astrocyte cultures was between 80
and 90%, as described previously [58], determined by
immunofluorescent staining using glial fibrillary acidic pro-
tein (GFAP) antibody (1:6000; DAKO, Glostrup, Denmark).
Purity of primary microglial cultures was between 90 and
94% as determined by immunofluorescent staining using
Iba1 antibody (1:1000; WAKO Chemicals USA).
Treatments
Astrocytes and microglia cultured on 2 μg/cm2 PLL-
coated 6-well plates (Nunc) were incubated for 48 h in
medium alone (control) or with lipopolysaccharide (LPS,
E. coli 055-B5, Difco, 100 ng/ml), human recombinant
(rec) transforming growth factor (TGF)-β1 (BioLegend),
human rec TGF-β2 (BioLegend), rat rec interleukin (IL)-
1β (Glaxo), rat rec tumor necrosis factor (TNF)-α
(Biolegend), rat rec TNF-α+IL-1β, rat rec interleukin
(IL)-4 (BioVision), rat rec interleukin (IL)-6 (gift from
Steve Poole), or rat rec interleukin (IL)-10 (Pharmingen)
(all 20 ng/ml). In addition, astrocytes and ECM depos-
ited by astrocytes were treated for 48 h with TNF+IL-1β
in the absence or presence of 10 μM of the bona fide
dihydroisoxazole TG2 activity inhibitor ERW1041E
(Quinolin-3-ylmethyl(S)-2-((((S)-3-bromo-4,5-dihydro-
isoxazol-5-yl)methyl)carbamoyl)pyrrolidine-1-carboxyl-
ate) diluted in 0.1% (v/v) dimethyl sulfoxide (DMSO);
kind gift from C. Khoshla, Stanford University, USA)
[59–61]. Astrocytes were alternatively treated with
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exogenous recombinant guinea pig TG2 (Sigma-Al-
drich) in pathophysiological concentrations (0.13 and
1.3 μM) according to previously published studies [62, 63]
for 48 h. Additionally, deposited ECM, after removal of
astrocytes, was treated with 0.64 μM exogenous recom-
binant guinea pig TG2 (Sigma-Aldrich) for 16 h com-
bined with a pre-incubation with a selective inhibitor of
TG2 (Z-DON, 1 μM, Zedira) diluted in 0.001% DMSO
or only with DMSO for 30 min (min) at 37 °C. In some
experiments, astrocytes were cultured in 8-well Lab-
Tek Permanox chamber slides (Nunc) or 6-well plates
(Nunc) coated with 2 μg/cm2 laminin (mixture of
laminin-1 and laminin-2, from Sigma-Aldrich) instead
of PLL.
Lentiviral downregulation of TG2
TG2 was downregulated in primary rat astrocytes by
lentiviral transduction with TG2 specific shRNA. There-
fore, astrocytes were plated on a laminin (2 μg/cm2;
Sigma-Aldrich) coated 12-well plate (0.2 × 106 cells/well,
Nunc). The following day, 0.2 × 106 infectious units of
virus (IFU) of lentiviral particles (Santa Cruz, sc-270266-
V for rat TG2 shRNA, or sc-108080 for control scram-
bled shRNA) were added to the cells. The next day, the
same amount of lentiviral particles was added to the
cells. The medium was changed the following day, and
the cells were left for 5 days before treatment with TNF-
α+IL-1β.
Sample collection
Whole cell lysates
Whole cell lysates were obtained by homogenizing the
cells in ice-cold lysis buffer containing 20 mM tris-HCl
pH 7.5, 137 mM NaCl, 1 mM ethylenediaminetetraacetic
acid, 1% NP40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 50 mM dithiothreitol (DTT),
100 μM phenylmethanesulfonyl fluoride (PMSF), 7.5 μM
pepstatin-A, 10 μM leupeptin, and 0.75 μM aprotinin
(all from Sigma-Aldrich).
Transglutaminase activity lysates
For transglutaminase (TG) activity measurements, cells
were collected in tris-buffered saline (TBS), pH 7.5, con-
taining 100 μM PMSF, 7.5 μM pepstatin-A, 10 μM leu-
peptin, and 0.75 μM aprotinin (all from Sigma-Aldrich).
ECM lysates
For the collection of ECM samples, cells were removed
after washing with TBS at room temperature (RT), by incu-
bation (5 min) with 50 mM NH4OH+ 0.05% Triton-100
(Sigma-Aldrich). This was followed by incubation (5 min)
with 50 mM NH4OH. Any remaining cell fractions were
washed away by repeated wash steps with TBS. The ECM
was incubated for 1 h at 37 °C with DNAse (10 U/ml,
Promega) in a buffer (pH 7.9) containing 4.84 g/L tris,
0.58 g/L NaCl, 0.57 g/L MgCl2, and 1.95 g/L CaCl2. The
ECM was again washed with TBS and collected in ice-cold
lysis buffer as described for the whole cell lysates.
Sample preparation
After sample collection, homogenates of whole cell lysate
samples and TG activity samples were sonicated (Branson
“Sonifier 250”; output 1, duty 30%, 8 pulses) and cleared by
centrifugation (20,000 g for 10 min at 4 °C), and protein
concentrations of supernatants were determined by the
BCA method (Pierce Biotechnology, Perbio Science, Etten-
Leur, The Netherlands). Samples were heated for 10 min at
95 °C. ECM samples were not subjected to sonication or
heating to maintain the integrity of the ECM aggregates.
Western blotting
Equal amounts of protein (20 μg) were subjected to 8%
SDS-polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane (Li-Cor Biosciences, Lincoln, NE,
USA). Membranes were blocked at RT with Odyssey
blocking buffer (Li-Cor Biosciences) diluted 1:1 with TBS.
Membranes were incubated overnight at 4 °C with mouse
anti-TG2 (ab3, Neomarkers 1:2000), rabbit anti-fibronectin
(Neomarkers, 1:1000), or mouse anti-β-actin (Abcam,
1:5,0000) antibodies. After several washes with TBS con-
taining 0.1% triton (TBS-T), blots were incubated for 1 h at
RT with corresponding goat anti-rabbit or donkey anti-
mouse IRDye 800CW IgG’s (1:10,000, Li-Cor Biosciences)
for subsequent antigen detection. All antibody solutions
were prepared in the Odyssey blocking buffer (Li-Cor
Biosciences) diluted 1:1 with TBS-T. After washing with
TBS-T and TBS, membranes were scanned for fluorescence
emission at 800 nm, using an Odyssey infrared imaging sys-
tem (Li-Cor Biosciences). Bands were visualized, and their
signal intensities were measured using the Odyssey Sa In-
frared scanning software (version 1.1, Li-Cor Biosciences).
Transglutaminase activity assay
TG activity was measured using the commercially available
TG Covtest Transglutaminase Colorimetric Microassay
(Covalab, Villeurbanne, France), which uses immobilized
CBZ-Gln-Gly as the first substrate and biotinylated-
cadaverine (biotin-Cd) as second substrate of the enzyme.
To determine the amount of TG2 activity among the TG
activity measured, samples were pre-incubated with a
selective inhibitor of TG2 (Z-DON, 1 μM, Zedira) diluted
in 0.001% DMSO or only with DMSO for 30 min at RT.
The assay was performed following the manufacturer’s
instructions [64]. In brief, 10 μg/well of each sample was
incubated with 50 μl/well of biotin-Cd solution containing
CaCl2 for 1 h at 37°C on the CBZ-Gln-Gly coated plates.
At the end of the incubation period, plates were washed
three times with TBS (pH 7.5) containing 0.1% Tween 20.
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Then, 100 μl/well of streptavidin-labeled horseradish perox-
idase (HRP) diluted to 1:2000 was added to the wells and
incubated for 1 h at RT. After washing, peroxidase activity
was revealed using 100 μl/well of 0.01% H2O2 as HRP
substrate and (0.1 mg/ml) tetramethylbenzidine as electron
acceptor (chromogen). The reaction was stopped by the
addition of 2.5 N H2SO4, and TG activity was detected by
absorbance measurement of streptavidin-labeled peroxidase
activity in each well on a microplate reader (SpectraMax
250, Molecular Devices, Sunnyvale, CA, USA) at 450 nm.
Guinea pig TG2 (T5398, Sigma-Aldrich) was used as a
standard. One unit of guinea pig TG2 will catalyze the
formation of 1.0 μmole of hydroxamate per min from Na-
Z-Gln-Gly and hydroxylamine at pH 6.0 at 37 °C.
Immunocytochemistry
Astrocytes (4.0 × 104/well) were plated on laminin (2 μg/
cm2, Sigma-Aldrich) or PLL (2 μg/cm2, Sigma-Aldrich)
coated 8-well Lab-Tek Permanox chamber slides (Nunc)
and treated with TGF-β1 (for ECM stainings only) or a
combination of TNF-α + IL-1β cytokines (20 ng/ml each)
for 48 h. Alternatively, exogenous recombinant guinea
pig TG2 (0.13 and 1.3 μM, Sigma-Aldrich) was added
for 48 h to untreated astrocytes. Astrocytes were fixed in
ice-cold methanol for 10 mins and washed in TBS. Non-
specific binding was blocked with 3% bovine serum
albumin in TBS containing 0.05% triton (TBS-T, pH 7.6)
for 30 min at RT. Subsequently, astrocytes were double-
labeled with mouse anti-TG2 (ab1, Neomarkers, 1:300)
and the astrocytic marker rabbit anti-GFAP (DAKO,
1:4000) or with rabbit anti-fibronectin (Millipore, 1:200)
to examine TG2 localization in astrocytes and any co-
localization with fibronectin, respectively. Triton was
alternatively omitted from all the incubation steps
during double stainings to detect TG2 and fibronectin
on the cell surface. Prior to ECM stainings, astrocytes
were removed as described before. Triton was not omit-
ted for the staining of the ECM. Secondary antibodies
used were the appropriate Alexa Fluor© (488 or 594)-
conjugated IgG’s (Molecular Probes, 1:400). After wash-
ing in TBS, astrocytes were cover-slipped in polyvinyl
alcohol mounting medium with DABCO (Sigma-Aldrich)
and examined using a confocal microscope (Leica TSC-
SP2-AOBS; Leica Microsystems, Wetzlar, Germany).
Filter trap assay
ECM lysates were treated for 30 min at RT with 150 mM
DTT to break down disulfide bonds and to obtain stable
aggregates. Equal amounts of ECM samples (12 μg) were
applied to a cellulose acetate membrane (GE water and
process technologies) using a filter trap assay apparatus
(FTA, Bio-Dot SF microfiltration apparatus, Bio-Rad).
This apparatus was coupled to a vacuum-pump in order
to wash through the monomers and dimers of ECM
aggregates and trap aggregates larger than the pore-size of
5 μm of the membrane. Approximately 5 min after sample
application, the membrane was washed in PBS and
incubated overnight at 4 °C with rabbit anti-fibronectin
(Neomarkers, 1:1000) antibodies. For subsequent antigen
detection, blots were incubated for 2 h with corresponding
goat anti-rabbit IRDye 800CW IgG’s (1:10,000, Li-Cor
Biosciences). After washing with TBS-T and TBS, mem-
branes were scanned for fluorescence emission at 800 nm,
using the same Odyssey infrared imaging system (Li-Cor
Biosciences) as used for western blotting.
Statistical analysis
Normal distribution of the data was tested using the
Shapiro-Wilk procedure. One-way analysis of variance was
performed followed by Dunnett’s post hoc test for multiple
comparisons by using IBM SPSS software, version 20.0
(IBM Corp., NY, USA). P < 0.05 was considered to represent
statistically significant differences, and a P value between
0.05 and 0.1 was regarded as a statistical trend.
Results
Astrocytes had higher TG2 and fibronectin protein levels
than microglia
We first examined whether primary rat astrocytes and
microglia produced TG2 and fibronectin. Under control
conditions and after treatment with LPS, astrocytes
expressed more TG2 and fibronectin than microglia
(Additional file 1). Upon subsequent treatment of astro-
cytes and microglia with a variety of inflammatory media-
tors, TG2 protein levels were significantly increased after
LPS, TNF-α+IL-1β, or IL-4 treatment (p < 0.001 for all,
Fig. 1a, b). Little protein was found in untreated microglia.
Incubation of microglia with the various mediators resulted
in significant changes in TG2 protein levels (Fig. 1d, e). LPS
or TNF-α+IL-1β treatment resulted in a significant increase
in TG2 protein level (p < 0.01 for LPS and p = 0.001 for
TNF-α+IL-1β, Fig. 1d, e). Moreover, IL-4 treatment showed
a trend (p = 0.080) toward an increase in TG2 protein level
(Fig. 1e). Other conditions studied, i.e., TGF-β1, TGF-β2,
IL-1β, TNF-α, IL-6, and IL-10, did not show significant ef-
fects on TG2 protein level in astrocytes or microglia (Fig.
1a–e). Double bands at approximately 78 kDa were visible
and quantified for TG2 in most conditions studied. This
has been shown by others as well [65, 66] and could repre-
sent the full-length TG2 protein and the short TG2 protein
that is truncated at the 3′ end [67]. Fibronectin levels were
significantly increased in astrocytes after treatment with
TGF-β1 (P < 0.01, Fig. 1a, c), and TGF-β2 showed a trend
(P= 0.062, Fig. 1c) toward an increased fibronectin level.
Other conditions studied, i.e., LPS, IL-1β, TNF-α, TNF-
α+IL-1β, IL-4, IL-6, and IL-10, did not result in significant
effects on fibronectin protein levels in astrocytes (Fig. 1a, c).
Moreover, none of the treatments affected the level of
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fibronectin in microglia (Fig. 1d, f). Considering the minimal
amount of fibronectin detected in microglia (Fig. 1d), we
decided to continue our study with a focus on astrocytes.
TG2 expression and activity in astrocytes were increased
by inflammatory conditions
We subsequently visualized TG2 by immunohistochemistry
in astrocytes. Under control conditions, little TG2 immuno-
reactivity was observed (Fig. 2a), but a clear increase was
apparent in TG2 immunoreactivity in specific GFAP positive
astrocytes after 48 h of TNF-α+IL-1β treatment (indicated
by arrows in Fig. 2b). Inflammatory conditions not only
affected expression of TG2 in astrocytes, but also increased
its activity. In particular, LPS (P < 0.01) and TNF-α+IL-1β
(P < 0.001) increased TG activity by astrocytes (Fig. 2c)
which was reduced when adding the TG2 specific inhibitor
Z-DON to the activity assay, indicating that the measured
TG activity is mainly due to TG2. Of interest is that
although IL-4 increased TG2 protein level, it showed a
trend but did not significantly affect TG activity (Fig. 2c).
Fig. 1 TG2 and fibronectin protein levels in astrocytes and microglia. Primary rat astrocytes and microglia were treated for 48 h with a range of
inflammatory mediators. TG2 and fibronectin (FN) protein levels in astrocytes were detected by western blotting (a), which were subsequently
semi-quantified (b, c). TG2 and fibronectin (FN) protein levels in microglia were detected by western blotting (d), which were subsequently
semi-quantified (e, f). Representative blots of three independent experiments are shown. Each bar represents the mean + standard error of the mean of
signal intensities from blots of three separate experiments that were calculated as average percentage compared to control (**p< 0.01 and *** p< 0.001)
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TG2 and fibronectin were deposited in the ECM by
astrocytes
Astrocytes were subsequently plated onto the ECM protein
laminin to mimic the situation of an MS lesion, where
laminin expression is increased [22]. Moreover, laminin is
of interest because it is expressed by cultured astrocytes
from healthy subjects and MS patients [29], and laminin is
a myelination permissive ECM molecule [68–70]. Under
those conditions, we again examined the effect of inflam-
matory conditions on TG2 and fibronectin levels. LPS or
TNF-α+IL-1β treatment were as effective in enhancing
TG2 and fibronectin protein levels (P < 0.05 for both
treatments, Fig. 3a–c) as they were in astrocytes cultured
on PLL (Fig. 1). However, IL-4 did not affect TG2 protein
levels in astrocytes cultured on laminin (Fig. 3a, b) in
contrast to astrocytes cultured on PLL (Fig. 1a, b), while
fibronectin levels were not affected in astrocytes cultured
on both ECM proteins (Fig. 1a, c and Fig. 3a, c). TGF-β1
treatment did not affect TG2 protein levels in astrocytes
cultured on either PLL or laminin (Fig. 1a, b and Fig. 3a, b),
whereas fibronectin protein levels in astrocytes cultured on
laminin were slightly enhanced (Fig. 3a, c) but more signifi-
cantly when astrocytes were cultured on PLL (Fig. 1a, c).
We next examined the effect of different inflammatory
conditions on the extracellular deposition of endogenously
produced TG2 and fibronectin by astrocytes cultured on
Fig. 2 TG2 expression and activity in astrocytes. Primary rat astrocytes were treated for 48 h with medium alone as a control condition (CTRL) (a) or with
TNF-α+IL-1β (b). TG2 immunoreactivity (green) was detected in astrocytes (as indicated by arrows in b) which were visualized by the astrocytic marker glial
fibrillary acidic protein (GFAP, red). Representative images of three independent experiments are shown. Scale bar represents 50 μm. TG activity was
examined in protein samples of astrocytes that were treated for 48 h with a range of inflammatory mediators. Subsequent derived astrocyte protein lysates
were pre-incubated with a selective inhibitor of TG2 (Z-DON, 1 μM) diluted in 0.001% DMSO or only with DMSO for 30 min at room temperature (c). Each
bar represents the mean + standard error of the mean of measurements from three separate experiments that were calculated as average percentage
compared to control (**P< 0.01 and ***P< 0.001)
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laminin. Astrocytes were therefore first cultured on laminin
coated chamber slides and treated with TGF-β1 or a com-
bination of TNF-α+IL-1β cytokines for 48 h. The astrocytes
were then removed and the ECM, produced by these astro-
cytes during the 48 h incubation period, was immunohisto-
chemically stained for TG2 and fibronectin. Without
treatment, little extracellular TG2 and fibronectin immuno-
reactivity in the ECM could be detected (Fig. 3d). Similarly,
after TGF-β1 treatment of the cells, TG2 in the ECM was
almost undetectable (Fig. 3e), but fibronectin deposition
was clearly visible (Fig. 3e) and showed fibril-like structures.
Upon treatment with TNF-α+IL-1β, extracellular TG2
immunoreactivity was present in the ECM (Fig. 3f). This
treatment did not visibly affect the amount of fibronectin
deposited in the ECM, though co-localization between
TG2 and fibronectin was apparent under this condition
(indicated by arrows in Fig. 3f).
Exogenous TG2 affected astrocyte-derived fibronectin
deposition and cross-linking
To follow-up on the observation that TG2 can be extra-
cellular deposited by astrocytes, we determined if extra-
cellular TG2 can have an effect on fibronectin
deposition. As proof of principle, we applied exogenous
TG2 to untreated astrocytes plated onto laminin and
studied fibronectin deposition and aggregation. We
observed that within a pathophysiological range of TG2
concentrations, the concentration of 0.13 μM exogen-
ously added TG2 was visible in either the ECM or
interacting with astrocytes, but no visible effect on
fibronectin expression or deposition was observed
(Fig. 4b). When the TG2 concentration of 1.3 μM was
added to the cells, it resulted in a more general inter-
action with astrocytes and was possibly incorporated
into the astrocytes (Fig. 4c). In addition, this concentra-
tion of TG2 resulted in morphologically altered fibro-
nectin deposition which appeared with a more fibrillary
structure (as indicated by arrows in Fig. 4c). More-
over, adding 0.64 μM TG2 to the deposited ECM,
after removal of astrocytes, resulted in a significant
increase in astrocyte-derived fibronectin aggregates in
the ECM as detected by FTA (P < 0.001, Fig. 4d). Pre-
incubation of the ECM with the specific TG2 inhibitor
Z-DON partially, but significantly, reduced this
increase in fibronectin aggregates (P < 0.05, Fig. 4d),
indicating that TG2 activity contributes to an altered
morphology of the fibronectin deposited and to fibro-
nectin aggregation.
Fig. 3 TG2 and fibronectin are deposited in the ECM by astrocytes. Primary rat astrocytes were plated onto laminin (LAM) coated plastic and were treated
for 48 h with a range of inflammatory mediators. TG2 and fibronectin (FN) protein levels in whole cell lysates (WCL) of astrocytes were detected by
western blotting (a), which were subsequently semi-quantified (b, c). Each bar represents the mean + standard error of the mean of signal intensities from
blots of three separate experiments that were calculated as average percentage compared to control (*P< 0.05). Primary rat astrocytes were treated for
48 h with medium alone as a control condition (CTRL), TGF-β1 or TNF-α+IL-1β, after which astrocytes were removed. TG2 deposition (green) and
fibronectin deposition (FN, red) were examined by immunohistochemical staining of the extracellular matrix (d, e, and f). TG2 and fibronectin
showed co-localization in the extracellular matrix after TNF-α+IL-1β treatment (indicated by arrows in f). Representative images of three
independent experiments are shown. Scale bar represents 50 μm
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Endogenous TG2 affected the morphological appearance
of fibronectin
We next determined whether endogenously produced
TG2, enhanced by MS relevant inflammatory stimuli, is
involved in fibronectin deposition and aggregation. As
already found that TNF-α+IL-1β did not affect fibronec-
tin protein levels in astrocytes (Fig. 3c), we now
observed that it neither significantly affected aggregation
of extracellular fibronectin (Fig. 5a, b). Interestingly, the
morphological appearance of extracellular fibril-like
fibronectin deposits (Fig. 5c, see arrows) was clearly altered,
i.e., shorter and thinner fibrils, upon co-incubation with the
bona fide TG2 inhibitor ERW1041E (48 h) (Fig. 5d). Also,
after lentiviral downregulation of TG2 (37% TG2 protein left
of control scrambled shRNA treatment, data not shown),
the morphological fibril-like fibronectin deposition, as found
in astrocytes lentivirally transduced with control scrambled
shRNA (Fig. 5e, see arrows), was altered (Fig. 5f).
Discussion
In the present study, we demonstrated that certain inflam-
matory mediators enhance TG2 protein levels in astrocytes
and microglial cells. In addition, fibronectin protein levels
were elevated in astrocytes, but not microglial cells.
Although exogenous TG2 contributed to aggregation of
fibronectin produced by astrocytes, endogenously produced
TG2 contributed to the appearance of morphological fibril-
like fibronectin, but was not involved in fibronectin aggre-
gation under inflammatory conditions in vitro.
At first, the present study extends our previous observa-
tions in astroglia to microglia and additional inflammatory
treatment effects were studied. We now observed that
astrocytes produced more TG2 than microglia. To deter-
mine which inflammatory mediators affect TG2 protein
levels in rat astrocytes and microglial cells, the effect of a
wide range of inflammatory mediators was studied. Of
these LPS, TNF-α+IL-1β and IL-4 most prominently
Fig. 4 Exogenous TG2 affects astrocyte-derived fibronectin deposition and cross-linking. Primary rat astrocytes were plated on laminin coated plastic and
double immunocytochemical surface stainings detected fibronectin (FN, red) and TG2 (green) in untreated control astrocytes (CTRL) and in astrocytes that
were treated with exogenous TG2 (0.13 or 1.3 μM) for 48 h (a, b, and c). Exogenous TG2 resulted in morphologically altered fibronectin deposition
(indicated by arrows in c). Representative images of three independent experiments are shown. Scale bar represents 20 μm. Fibronectin (FN) aggregates
on laminin (LAM) coated plastic were studied after removal of untreated astrocytes that were allowed to produce extracellular matrix for 48 h. The
extracellular matrix was incubated with exogenous TG2 (0.64 μM, 16 h) and pre-incubated with the specific TG2 inhibitor Z-DON (1 μM) for 30 min at 37 °
C (d). Representative blots of four independent experiments are shown. Each bar represents the mean + standard error of the mean of signal intensities
from blots of four separate experiments that were calculated as average percentage compared to control (*P< 0.05 and ***P< 0.001)
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Fig. 5 (See legend on next page.)
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enhanced TG2 protein levels in both cell types, with a
higher fold increase in astrocytes. It has been shown before
by us and others that astrocytes can produce TG2 [50, 71,
72]. A recent study indicated that mouse microglial cells
and not astrocytes are the primary source of TG2 mRNA
[73]. Their contrasting observation may be due to differ-
ences in species, rats in our study and mice in theirs, and
developmental stage of the cells that can affect mRNA ex-
pression [74–76]. The responsiveness of glial cells to vari-
ous inflammatory mediators can be explained by the
presence of inflammatory factor-related response elements
in the promotor region of the TG2 gene [47, 77, 78], in-
cluding NF-κB (nuclear factor-kappa B), a transcription fac-
tor involved in the regulation of expression of many
inflammatory mediators [79].
Astrogliosis is considered to contribute to the scar
formation in MS lesions. As part of that process, astro-
and microglial cells produce ECM proteins to stabilize
the matrix which then becomes a non-permissive envir-
onment for regeneration, by depositing ECM proteins
that are often inhibitory to regeneration, e.g., chondro-
itin sulfate proteoglycans [24, 51, 80], hyaluronan [19,
81, 82], and fibronectin [29, 30, 69]. In the present study,
we observed that rat astrocytes had higher fibronectin
protein levels than microglial cells. This is in line with
other observations showing that ECM proteins are pre-
dominantly produced by astrocytes and to a lesser extent
by microglia and other glial cells [8, 29, 52, 53].
We thus subsequently focused on the regulation of
TG2 and fibronectin production in astrocytes during
inflammatory conditions. Besides intracellular expression
of TG2, we observed TG2 protein on the surface of
astrocytes which was also regulated by inflammatory
mediators (data not shown). This is in agreement with
our previous finding that TG2 is upregulated in the
presence of IL-1β and TNF-α at the cell surface of rat
astrocytes, where we showed that this coincided with an
increased adhesion to and interaction of astrocytes with
the ECM protein fibronectin, creating an environment
for astroglial scarring [50]. In addition to TG2 protein
production, its activity is essential to mediate possible
cross-linking of fibronectin. We now showed that TG2
activity was present and increased by LPS or TNF-α+IL-
1β, but was not significantly affected by IL-4 treatment.
This last observation was unexpected, as the amount of
TG2 protein was enhanced, and in human macrophages,
IL-4 does increase TG2 activity [83]. This may suggest that
in astrocytes, IL-4-generated TG2 has a function different
from protein cross-linking. In agreement with our finding
that astrocytes respond to inflammatory conditions by
increasing their TG2 expression and activity, others have
shown, in different cell types and tissues, such as lung and
liver cells and cartilage tissue, that inflammatory cytokines,
including TNF-α and IL-1β, can indeed upregulate TG2
expression and activity [47, 77, 84–86].
It is of interest to note that the effects some cytokines
had on astrocytes that were cultured on PLL, such as an
increase in TG2 protein levels after IL-4 treatment and
an increase in fibronectin protein levels after TGF-β1
treatment, were no longer present when astrocytes were
cultured on laminin. This is in line with previous work
that showed that ECM composition determines astrocyte
responses to inflammatory stimuli [87] and extends on
our previous observations [50]. As in brain lesions
induced by damage, i.e., MS, more ECM proteins such
as laminin are present [22, 27], we considered it relevant
to pursue our studies with astrocytes exposed to laminin
in the culture dish. The subsequent effect of inflamma-
tory mediators in our study on either TG2 or fibronectin
was not confined to protein expression inside the cells,
but extracellular deposition of both TG2 and fibronectin
was also affected by TNF-α+IL-1β and TGF-β1. Under
inflammatory conditions, including MS, it is well known
that astrocytes contribute to ECM production and
deposition [8, 13, 21, 88–90]. In our present study, we
showed that the addition of exogenous TG2 to astro-
cytes resulted in a fibril-like morphology of the fibronec-
tin deposited and increased fibronectin aggregation. This
protein aggregation was partially reduced by the TG2-
specific inhibitor Z-DON, which suggests that TG2
activity can, at least partly, mediate aggregation of
astrocyte-derived fibronectin, shown here as fibronectin
fibrils. Alternatively, a non-enzymatic, non-covalent
interaction of TG2 with fibronectin [91] might contrib-
ute to the altered morphology of the fibronectin. Such
TG2-fibronectin interaction stabilizes the ECM by
enhancing fibronectin matrix formation and interaction
with other proteins, such as integrins, syndecan-4,
(See figure on previous page.)
Fig. 5 Endogenous TG2 affects the morphological appearance of fibronectin. Fibronectin (FN) aggregates on laminin (LAM) coated plastic were studied after
removal of astrocytes that were allowed to produce extracellular matrix during 48 h of TNF-α+IL-1β treatment (a, b). Representative blots of four independent
experiments are shown. Each bar represents the mean + standard error of the mean of signal intensities from blots of four separate experiments that were
calculated as average percentage compared to control. Primary rat astrocytes were treated with TNF-α+IL-1β for 48 h plated on laminin coated plastic.
Immunocytochemical double stainings showed immunoreactivity of fibronectin (FN, red) and TG2 (green) in astrocytes (c, d, e, and f).
Astrocytes were co-incubated with TNF-α+IL-1β and the TG2-specific inhibitor ERW1041E (10 μM for 48 h) or DMSO (d) or treated with
TNF-α+IL-1β after lentiviral downregulation of TG2 (TG2 knockdown (KD)) compared to scrambled knockdown (scrambled KD) (f). Fibril-like
fibronectin deposition (indicated by arrows in c and e) was morphological altered after treatment with ERW1041E and after lentiviral
downregulation of TG2. Scale bar represents 20 μm
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growth factor receptors, and other cell surface or ECM
proteins [32, 92–94].
Under inflammatory conditions, as present in MS
lesions, when endogenous TG2 protein levels were
enhanced by TNF-α+IL-1β treatment of astrocytes,
fibronectin deposits showed morphologically a fibril-like
structure. This was similar as shown by addition of
exogenous TG2, while now fibronectin aggregation was
absent. These observations are suggestive for a role of
TG2 in the assembly of fibronectin into a fibril-like
structure without being aggregated. Indeed, treatment of
astrocytes with the TG2 inhibitor ERW1041E or lenti-
viral downregulation of TG2 with TG2-specific shRNA
in astrocytes altered the morphology of TNF-α+IL-1β-
induced fibronectin deposits, by reducing fibril size and
thickness, indicating that TG2 is involved in this process
in vitro. Though, no clear fibronectin aggregates were
observed, which were evident when TG2 was exogen-
ously added to the astrocytes. This is in line with the
observations that TG2 can lead to a switch from intra-
molecular cross-linking to intermolecular protein cross-
linking giving rise to protein aggregate formation [63].
Thus, we cannot exclude that the level of TG2 protein
present in astrocytes under inflammatory conditions in
vitro is able to alter the conformation of fibronectin to a
fibril-like structure, but it is not able to form cross-
linked protein aggregates. In support of this, we also did
not observe fibronectin aggregation in the cuprizone
model of demyelination in which astrocytes become
hypertrophic and express TG2 and fibronectin [49].
However, fibronectin deposition is found in MS lesions as
a complex network of fibrils of high molecular weight
aggregates, which impairs remyelination [29]. Fibronectin
aggregation, as defined by deoxycholate-insolubility, is
likely the result of strong, non-covalent protein-protein
interactions [31, 95, 96]. As a consequence, we might
hypothesize that during inflammatory lesion formation in
MS and concomitant deposition of ECM proteins,
astrocyte-derived TG2, only in the presence of infiltrating
leukocytes or their derived factors, can increase the forma-
tion of fibronectin fibril-like deposits which aggregate and
may contribute to the process of scarring and subsequent
impaired remyelination.
Conclusions
The results presented here demonstrate that under
inflammatory conditions in vitro, TG2 protein levels are
enhanced in astrocytes and microglia. In addition, in
particular, astrocytes produce ECM proteins, i.e., fibro-
nectin, that can be cross-linked and aggregated by
exogenously added TG2. Endogenously produced TG2,
enhanced by inflammatory stimuli, is involved in the
appearance of morphological fibril-like fibronectin
deposits, but does not lead to cross-linked fibronectin
aggregates. Thus, our in vitro observations suggest that
during MS lesion formation, when inflammatory media-
tors are produced, astrocyte-derived TG2 may contrib-
ute to ECM rearrangement and subsequent astroglial
scarring. The possibility to intervene with the formation
of fibronectin fibril-like deposits may open avenues to
reduce the astroglial scarring process, not only in MS
but also in other CNS disorders, when scarring prohibits
regeneration [97].
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